NEW YORK (GenomeWeb) – Natera is aiming to raise $75 million in a follow-on public offering of shares of its common stock, the firm reported after the close of the market on Tuesday. It also expects to grant underwriters a 30-day option to purchase up to an additional $11.25 million worth of common stock.

JP Morgan, Morgan Stanley, and Cowen are acting as joint book-running managers for the offering, which will be made only through a prospectus and related prospectus supplement, copies of which can be obtained from JP Morgan Securities.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oct
02

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.